Related Experiment Video
Updated: Feb 3, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
MicroRNA-93 mediates cabergoline resistance by targeting ATG7 in prolactinoma
Zerui Wu1, Lin Cai2, Jianglong Lu3
1Z Wu, Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Abstract:
To date, the management of dopamine agonist (DA)-resistant prolactinomas remains a major clinical problem. Previously, we determined that miRNA-93 expression increases in DA-resistant prolactinomas; however, the role of miRNA-93 in the DA resistance remains largely unexplored. Hence, this study aimed to investigate the susceptibility of tumor cells to cabergoline (CAB) and the autophagy changes in MMQ and GH3 cells after miRNA-93 overexpression or inhibition. We used bioinformatics to identify the potential target of miRNA-93. Subsequently, we analyzed the correlation between miRNA-93 and autophagy-related 7 (ATG7) using protein expression analysis and luciferase assays. Furthermore, the change in the effect of miRNA-93 was measured after ATG7 overexpression. miRNA-93 expression was elevated in DA-resistant prolactinomas, whereas the expression of its identified target, ATG7, was downregulated. miRNA-93 overexpression suppressed the cytotoxic effect of CAB in MMQ and GH3 cells. In contrast, miRNA-93 downregulation enhanced CAB efficiency and promoted cell autophagy, eventually resulting in apoptosis. These results were further confirmed in in vivo xenograft models in nude mice. ATG7 overexpression could reverse the inhibitory effect of miRNA-93 on CAB treatment. Taken together, our results suggest that miRNA-93 mediates CAB resistance via autophagy downregulation by targeting ATG7 and serves as a promising therapeutic target for prolactinoma.
Insights
MicroRNA-93 (miRNA-93) drives resistance to dopamine agonist (DA) therapy in prolactinomas by inhibiting autophagy via targeting ATG7. Downregulating miRNA-93 may restore DA sensitivity and promote tumor cell death.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Dopamine agonist (DA)-resistant prolactinomas present a significant clinical challenge.
- Increased microRNA-93 (miRNA-93) expression was previously observed in DA-resistant prolactinomas, but its role is unclear.
Purpose of the Study:
- To investigate the role of miRNA-93 in mediating resistance to cabergoline (CAB) in prolactinoma cells.
- To explore the impact of miRNA-93 on cellular autophagy and its relationship with autophagy-related 7 (ATG7).
Main Methods:
- Bioinformatic analysis to identify miRNA-93 targets.
- In vitro studies using MMQ and GH3 cells with miRNA-93 overexpression or inhibition.
- Analysis of autophagy markers and cell viability.
- Protein expression analysis and luciferase assays to confirm miRNA-93 and ATG7 interaction.
- In vivo xenograft models in nude mice.
Main Results:
- miRNA-93 expression was elevated, and ATG7 expression was downregulated in DA-resistant prolactinomas.
- miRNA-93 overexpression reduced CAB's cytotoxic effect, while miRNA-93 inhibition enhanced CAB efficacy and induced apoptosis via autophagy.
- ATG7 overexpression reversed the resistance induced by miRNA-93.
- Findings were validated in vivo.
Conclusions:
- miRNA-93 contributes to cabergoline resistance in prolactinomas by downregulating autophagy through targeting ATG7.
- miRNA-93 represents a potential therapeutic target for overcoming DA resistance in prolactinoma treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

